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After the publication of this work [1], we noted that
owing to an inadvertent mistake, the description of the
chemotherapy schedule shown in the Methods was dif-
ferent from that shown in the Abstract and the duration
of S-1 treatment in the initial chemoradiotherapy was
inadequately described in Figure 1. Therefore, Methods
and Figure 1 were modified accordingly.
In the “Chemoradiotherapy” section in the Methods,
the 1st and 3rd paragraphs should read as follows:
“The chemoradiotherapy protocol consisted of admin-
istration of S-1 plus biweekly cisplatin and radiation
(Figure 1). The initial chemoradiotherapy schedule was
for 6 weeks: S-1 was orally administered twice daily from
the evening of day 1 to the morning of day 15, and the
total dose was based on the patient’s body surface area* Correspondence: surgeontsune@yahoo.co.jp
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Figure 1 Chemoradiotherapy consisted of combination chemotherap
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unless otherwise stated.(BSA), as follows: <1.25 m2, 80 mg; 1.25–1.5 m2,
100 mg; and >1.5 m2, 120 mg. An escalating dose of cis-
platin was administered by infusion over 1 h on days 1
and 15 without infusional hydration. The starting dose
(level 1) of cisplatin was 15 mg/m2, the second dose
(level 2) was 20 mg/m2, and the third dose (level 3) was
25 mg/m2.”
“After initial chemoradiotherapy, one cycle of combin-
ation chemotherapy with S-1 plus biweekly cisplatin was
delivered. This consisted of 42 days of S-1 administered
from the evening of day 1 to the morning of day 29 and
of cisplatin administered on days 1, 15, and 29.”
In “Figure 1,” based on the description in the manu-
script, the duration of S-1 treatment in the initial che-
moradiotherapy was revised to 1–15 days from 1–22
days (Figure 1).y with S-1, biweekly cisplatin, and fractionated radiation therapy.
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